U.S. markets closed
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • Dow 30

    31,261.90
    +8.77 (+0.03%)
     
  • Nasdaq

    11,354.62
    -33.88 (-0.30%)
     
  • Russell 2000

    1,773.27
    -2.96 (-0.17%)
     
  • Crude Oil

    112.70
    +0.49 (+0.44%)
     
  • Gold

    1,843.40
    +2.20 (+0.12%)
     
  • Silver

    21.75
    -0.16 (-0.74%)
     
  • EUR/USD

    1.0560
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • GBP/USD

    1.2488
    +0.0013 (+0.11%)
     
  • USD/JPY

    127.8760
    +0.0820 (+0.06%)
     
  • BTC-USD

    29,256.45
    -768.73 (-2.56%)
     
  • CMC Crypto 200

    652.20
    -21.17 (-3.14%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

WHO Issues Emergency Use Listing to Novavax-Serum Institute's COVID-19 Vaccine

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The World Health Organization issued an emergency use listing to Covovax, Serum Institute of India's version of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine.

  • The vaccine, named Covovax, is produced by the Serum Institute of India and is part of the COVAX facility portfolio.

  • It requires two doses and is stable at 2 to 8 °C refrigerated temperatures.

  • Related Link: Serum Institute's CEO Expects To Launch Novavax Vaccine For Kids In Six Months: Reuters.

  • The vaccine uses a novel platform and is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein.

  • The originator product produced by Novavax, named Nuvaxovid, is currently under assessment by the European Medicines Agency (EMA).

  • WHO will complete its assessment of this vaccine once the EMA has issued its recommendation.

  • Price Action: NVAX shares are up 11% at $216.32 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.